PTGES

Across TCGA pan-cancer cohorts, PTGES mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTGES data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PTGES mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTGES expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where PTGES mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.241	0.643	<.001	53	view →
HNSC	DFS	Median	All	0.757	0.509	.001	29	view →
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	21	view →
UCEC	OS	Tertile	III,IV	0.315	1.000	.042	8	view →
GBM	OS	Quartile	All	0.688	0.243	.016	4	view →
LUAD	OS	Quartile	III,IV	0.804	0.310	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTGES–PDAC (DFS)

Open the PDAC breakdown →